Pfizer Ups Ante With 2nd Offer For AstraZeneca, Assures U.K. Government
This article was originally published in The Pink Sheet Daily
Executive Summary
By upping its offer for AstraZeneca to £50 a share from £46.61, Pfizer is underscoring its intent to buy Britain’s second-biggest drug maker - a takeover which would be the largest acquisition of a British company by a foreign business and looks certain to cause consternation within the U.K. government, its life sciences sector and academia.